



FACSIMILE COVER SHEET

SALIWANCHIK, LLOYD & SALIWANCHIK

A Professional Association
2421 N.W. 41st Street
Suite A-1
Gainesville, FL 32606

Telephone (352) 375-8100
Facsimile (352) 372-5800

TO:	Group Art Unit 1645	FROM:	Frank C. Eisenschenk, Ph.D.
COMPANY:	U.S. Patent & Trademark Office	DATE:	April 1, 2002
FAX NO.:	1-703-872-9306	NO. OF PAGES:	6
			(INCLUDING COVER SHEET)

SUBJECT/MESSAGE:

U.S. Patent Application Docket No. GEN-100D1
HUMAN DEFENSIN DEF-X
(Bougueleret, Chumakov)
Serial No. 10/045,180; Filed October 18, 2001
Your Ref.: 30.US2.DIV

**THIS IS AN OFFICIAL DOCUMENT.
PLEASE DELIVER IMMEDIATELY.**

Attachments: Information Disclosure Statement
PTO/SB/08 (3 pages)

The information contained in this facsimile message is intended only for the personal and confidential use of the designated recipients named above. This message may be an attorney-client communication, and as such is privileged and confidential. If the reader of this message is not the intended recipient or an agent responsible for delivering it to the intended recipient, you are hereby notified that you have received this document in error, and that any review, dissemination, distribution, or copying of this message is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone and return the original message by mail. Thank you.

If you do not receive all pages or if any transmission is not legible, call the sender at (352) 375-8100.

TRANSACTION REPORT

P. 01

APR-01-2002 MON 04:04 PM

FOR: SALIWANCHIK, LLOYD & SALIWA 352 372 5800

DATE	START	RECEIVER	TX TIME	PAGES	TYPE	NOTE	M#	DP
APR-01	04:01 PM	17038729306	3' 10"	6	SEND	OK	158	

TOTAL : 3M 10S PAGES: 6

FACSIMILE COVER SHEET

SALIWANCHIK, LLOYD & SALIWANCHIK

A Professional Association
2421 N.W. 41st Street
Suite A-1
Gainesville, FL 32606


Telephone (352) 375-8100
Facsimile (352) 372-5800


TO:	Group Art Unit 1645	FROM:	Frank C. Eisenschenk, Ph.D.
COMPANY:	U.S. Patent & Trademark Office	DATE:	April 1, 2002
FAX NO.:	1-703-872-9306	NO. OF PAGES:	6
		(INCLUDING COVER SHEET)	

SUBJECT/MESSAGE:

U.S. Patent Application Docket No. GEN-100D1
HUMAN DEFENSIN DEF-X
(Bougueleret, Chumakov)
Serial No. 10/045,180; Filed October 18, 2001
Your Ref.: 30.US2.DIV

THIS IS AN OFFICIAL DOCUMENT.





COPY

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office on April 1, 2002.

Frank C. Eisenschenk

Frank C. Eisenschenk, Ph.D., Patent Attorney

INFORMATION DISCLOSURE STATEMENT

Examining Group 1645

Patent Application

Docket No. GEN-100D1

Serial No. 10/045,180

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : (Unassigned)
Art Unit : 1645
Applicant(s) : Lydie Bougueleret and Ilya Chumakov
Serial No. : 10/045,180
Filed : October 18, 2001
For : HUMAN DEFENSIN POLYPEPTIDE DEF-X, GENOMIC DNA AND cDNA,
COMPOSITION CONTAINING THEM AND APPLICATIONS TO DIAGNOSIS AND
TO THERAPEUTIC TREATMENT.

Assistant Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 AND 1.98

Sir:

In accordance with 37 C.F.R §§ 1.97 and 1.98, Applicants would like to bring to the attention of the Examiner, the references cited in the following patent application:


U.S. Serial No. 09/486,580, filed February 25, 2000.

37 C.F.R. § 1.98(d) states that a copy of any patent, publication, or other information listed in an information disclosure statement is not required to be provided if it was previously cited by or submitted to the Office in a prior application, provided that the prior application is properly identified in the statement and relied on for an earlier filing date under 35 U.S.C. § 120.

As copies of the references cited on the attached form PTO-1449, can be found in patent application Serial Number 09/486,580, filed February 25, 2000, copies of those references are not provided herewith. The subject application, Serial No. 10/045,180, claims the benefit under 35 U.S.C. § 120 of the filing date of patent application Serial No. 09/486,580. Accordingly, Applicants respectfully request that the copies of references supplied in the Information Disclosure Statement of the 09/486,580 application, as well as references cited during prosecution thereof, be made of record in this application.

Applicants respectfully assert that the substantive provisions of 37 C.F.R. §§ 1.56, 1.97, and 1.98 are met by the foregoing statements.

Respectfully submitted,



Frank C. Eisenschenk, Ph.D.

Patent Attorney

Registration No. 45,332


Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: Saliwanchik, Lloyd & Saliwanchik
A Professional Association
2421 N.W. 41st Street, Suite A-1
Gainesville, FL 32606-6669

FCE/an

Attachment: PTO Form SB/08A (Substitute for Form 1449)



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/045,180
				Filing Date	October 18, 2001
				First Named Inventor	Lydie Bougueleret
				Art Unit	1645
				Examiner Name	Unassigned
Sheet	1	of	3	Attorney Docket Number	GEN-100D1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
	U1	US- 5,242,902	09-07-1993	Murphy et al.	All
	U2	US- 5,641,497	06-24-1997	Bevins et al.	All
	U3	US-			
	U4	US-			
	U5	US-			
	U6	US-			
	U7	US-			
	U8	US-			
	U9	US-			
	U10	US-			
	U11	US-			
	U12	US-			
	U13	US-			
	U14	US-			
	U15	US-			
	U16	US-			
	U17	US-			
	U18	US-			
	U19	US-			
	U20	US-			


FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶ *
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
	F1	WO 89/11291	11-30-1989	Invitron Corp.	All	
	F2	WO 94/21672	09-29-1994	Regents of U. of Calif.	All	
	F3	WO 95/32287	11-30-1995	Magainin Pharmaceuticals	All	
	F4					
	F5					
	F6					
	F7					
	F8					
	F9					
	F10					

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/045,180	
			Filing Date	October 18, 2001	
			First Named Inventor	Lydie Bougueleret	
			Group Art Unit	1645	
			Examiner Name	Unassigned	
			Attorney Docket Number	GEN-100D1	
Sheet	2	of	3		



NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R1	BEVINS, et al. [1996] "Human Enteric Defensin Genes: Chromosomal Map Position and a Model for Possible Evolutionary Relationship", <i>Genomics</i> , 31:95-106	
	R2	GANZ et al. [1994] "Defensins", <i>Current Opinion in Immunology</i> , 6:584-589	
	R3	GANZ et al. [1995] "Defensins", <i>Pharmac Ther.</i> , 66:191-205	
	R4	HUGHES, A. [1999] "Evolutionary Diversification of the Mammalian Defensins", <i>CMLS, Cell. Mol. Life Sci.</i> 56:94-103	
	R5	HUGHES, A. et al. [1997] "Coordinated Amino Acid Changes in the Evolution of Mammalian Defensins", <i>J. Mol. Evol.</i> 44:675-82	
	R6	KAGAN et al. [1994] "Defensins: a Family of Antimicrobial and Cytotoxic Peptides", <i>Toxicology</i> , 87:131-149	
	R7	LEHRER et al. [1992] "Defensins: Endogenous Antibiotic Peptides from Human Leukocytes", <i>Ciba Foundation Symposium</i> 171:276-293	
	R8	LERNER R. [1982] "Tapping the Immunological Repertoire to Produce Antibodies of Predetermined Specificity", <i>Nature</i> 299:592-96	
	R9	MALLOW et al. [1996] "Human Enteric Defensins", <i>The Journal of Biological Chemistry</i> 271:4038-4045	
	R10	MARTIN et al. [1995] "Defensins and Other Endogenous Peptide Antibiotics of Vertebrates", <i>Journal of Leukocyte Biology</i> 58:128-136	
	R11	RAJ, P. [2000] "Large-scale Synthesis and Functional Elements for the Antimicrobial Activity of Defensins", <i>Biochem. J.</i> 347:633-41	
	R12	SPARKES et al. [1989] "Assignment of Defensin Gene(s) to Human Chromosome 8p23", <i>Genomics</i> 5:240-244	
	R13	WHITE et al. [1995] "Structure, Function, and Membrane Integration of Defensins", <i>Current Option in Structural Biology</i> 5:521-527	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	10/045,180
Filing Date	October 18, 2001
First Named Inventor	Lydie Bougueleret
Group Art Unit	1645
Examiner Name	Unassigned
Attorney Docket Number	GEN-100D1

Sheet 3 of 3

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R14	WILDE et al. [1989] "Purification and Characterization of Human Neutrophil Peptide 4, a Novel Member of the Defensin Family", <i>Journal of Biological Chemistry</i> 264 (19):11200-11203	
	R15		
	R16		
	R17		
	R18		
	R19		
	R20		
	R21		
	R22		
	R23		
	R24		
	R25		
	R26		

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.